Roche, Genentech try to calm jittery partners

A move by Roche and its newly acquired subsidiary Genentech to kill a trio of development pacts within just a few days has triggered some deep-seated fears that the pharma giant is winnowing out programs from its combined pipeline, according to a report in the San Francisco Business Times. Roche and Genentech are engaged in a wide range of pacts that pump millions of dollars into their partners' coffers. But the two companies insist that the rapid-fire execution of deals is not connected to any kind of new review process triggered by the merger. "Nothing's changed," a Genentech spokesperson told the weekly. "We're going over the same review process we've always had." Report   

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.